- Home
- YHGJ vs LEXX Comparison
YHGJ vs LEXX Comparison
Compare YHGJ & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YHGJ
- LEXX
- Stock Information
- Founded
- YHGJ 1975
- LEXX 2004
- Country
- YHGJ United States
- LEXX Canada
- Employees
- YHGJ N/A
- LEXX N/A
- Industry
- YHGJ Specialty Chemicals
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- YHGJ Industrials
- LEXX Health Care
- Exchange
- YHGJ Nasdaq
- LEXX Nasdaq
- Market Cap
- YHGJ 25.9M
- LEXX 23.9M
- IPO Year
- YHGJ 1997
- LEXX N/A
- Fundamental
- Price
- YHGJ $5.42
- LEXX $0.85
- Analyst Decision
- YHGJ
- LEXX Strong Buy
- Analyst Count
- YHGJ 0
- LEXX 1
- Target Price
- YHGJ N/A
- LEXX $4.00
- AVG Volume (30 Days)
- YHGJ 401.2K
- LEXX 1.4M
- Earning Date
- YHGJ 11-07-2025
- LEXX 11-25-2025
- Dividend Yield
- YHGJ N/A
- LEXX N/A
- EPS Growth
- YHGJ N/A
- LEXX N/A
- EPS
- YHGJ N/A
- LEXX N/A
- Revenue
- YHGJ $18,964,000.00
- LEXX $615,923.00
- Revenue This Year
- YHGJ N/A
- LEXX $46.98
- Revenue Next Year
- YHGJ N/A
- LEXX $17.26
- P/E Ratio
- YHGJ N/A
- LEXX N/A
- Revenue Growth
- YHGJ 5.70
- LEXX 49.85
- 52 Week Low
- YHGJ $4.35
- LEXX $0.77
- 52 Week High
- YHGJ $12.70
- LEXX $3.15
- Technical
- Relative Strength Index (RSI)
- YHGJ 58.82
- LEXX 42.56
- Support Level
- YHGJ $5.31
- LEXX $0.83
- Resistance Level
- YHGJ $10.29
- LEXX $0.92
- Average True Range (ATR)
- YHGJ 0.95
- LEXX 0.08
- MACD
- YHGJ 0.07
- LEXX -0.02
- Stochastic Oscillator
- YHGJ 50.14
- LEXX 10.47
About YHGJ Yunhong Green CTI Ltd.
Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.